You have read all your free articles, to continue reading subscribe to read the rest of this content.
The biopharmaceutical company announces the completion of enrollment in their Phase II proof-of-concept study of ABY-035 for moderate-to-severe psoriasis, AFFIRM-35. The double-blind, placebo controlled, Phase 2 proof-of-concept study (AFFIRM-35, NCT03591887) enrolled 100 moderate-to-severe psoriAlready a subscriber Login You have read all your free articles, to continue reading subscribe to read…
Oncopeptides has announced completion of enrollment in the phase 3 study OCEAN for the treatment of relapsed refractory multiple myeloma. The study includes 450 patients from more than 100 hospitals around the world. Results are expected to be presented later this year. About the OCEAN study OCAlready a subscriber Login…
Targovax has announced that the first patient has been dosed with cancer vaccine TG01 in the combination study with PD-1 checkpoint inhibitor (CPI) balstilimab in mutant RAS pancreatic cancer in the USA. The study is led by gastrointestinal cancer expert Dr. Anup Kasi in a three-way clinical collAlready a subscriber…
Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated 4-week data on the patient, who lives with advanced heart failure and has giveAlready a subscriber Login You…
